Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease | Hematology | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME

The effectiveness of COVID-19 vaccination remains unknown in patients with hematologic malignant disease who have an impaired humoral immunity from both treatment and disease. Phase 3 registration studies of COVID-19 vaccines excluded patients with immunosuppression or immunosuppressive therapies.1,2 Despite this, professional organizations suggest vaccination, or even its prioritization, for patients with cancer.3 As the US Centers for Disease Control loosens pandemic-related precautions for vaccinated people, a better understanding of the vaccine response among patients with hematologic malignant disease is critical.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Accepted for Publication: July 12, 2021.

Published Online: August 11, 2021. doi:10.1001/jamaoncol.2021.4381

Corresponding Author: Thomas A. Ollila, MD, Alpert Medical School of Brown University, Rhode Island Hospital, George Bldg, Ste 310, 593 Eddy St, Providence, RI 02903 (thomas_ollila@brown.edu).

Author Contributions: Dr Ollila had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Ollila, Lu, Rogers, Olszewski.

Acquisition, analysis, or interpretation of data: Ollila, Lu, Masel, Zayac, Paiva, Olszewski.

Drafting of the manuscript: Ollila, Zayac, Paiva, Olszewski.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Olszewski.

Administrative, technical, or material support: Ollila, Lu, Paiva, Rogers, Olszewski.

Supervision: Ollila, Olszewski.

Conflict of Interest Disclosures: Dr Olszewski reported research funding from Genentech, TG Therapeutics, Celldex Pharmaceuticals, and Precision Bio; grants from Acrotech Pharma, Adaptive Biotechnologies outside the submitted work. No other disclosures were reported.

Additional Contributions: In addition to the listed authors, we acknowledge the following individuals for their assistance with this study, none of whom were compensated for his or her contributions and all of whom agree to include their names here: John L. Reagan, MD (Brown Alpert School of Medicine); Peter Barth, MD (Brown Alpert School of Medicine); Rabin Niroula, MD; Gerard J. Nau, MD, PhD (Brown Alpert School of Medicine); Rani Chudasama, MD (Brown Alpert School of Medicine); Inna Yakirevich, NP (Division of Hematology/Oncology, Rhode Island Hospital); and Christopher Elco, MD, PhD (Brown Alpert School of Medicine).

References
1.
Baden  LR , El Sahly  HM , Essink  B ,  et al; COVE Study Group.  Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.   N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389PubMedGoogle ScholarCrossref
2.
Polack  FP , Thomas  SJ , Kitchin  N ,  et al; C4591001 Clinical Trial Group.  Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.   N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577PubMedGoogle ScholarCrossref
3.
Ribas  A , Sengupta  R , Locke  T ,  et al; AACR COVID-19 and Cancer Task Force.  Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited.   Cancer Discov. 2021;11(2):233-236. doi:10.1158/2159-8290.CD-20-1817PubMedGoogle ScholarCrossref
4.
Paiva  KJ , Grisson  RD , Chan  PA ,  et al.  Validation and performance comparison of three SARS-CoV-2 antibody assays.   J Med Virol. 2021;93(2):916-923. doi:10.1002/jmv.26341PubMedGoogle ScholarCrossref
5.
Stephenson  KE , Le Gars  M , Sadoff  J ,  et al.  Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.   JAMA. 2021;325(15):1535-1544. doi:10.1001/jama.2021.3645PubMedGoogle ScholarCrossref
6.
Walsh  EE , Frenck  RW  Jr , Falsey  AR ,  et al.  Safety and immunogenicity of two RNA-Based Covid-19 vaccine candidates.   N Engl J Med. 2020;383(25):2439-2450. doi:10.1056/NEJMoa2027906PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close